Dutch meniscus prosthesis receives FDA Breakthrough Device Designation
Dutch medical innovations are rarely granted the Breakthrough Designation by the FDA. Startup ATRO Medical from Nijmegen is the new kid on the block in orthopedics. This week their Trammpolin® meniscus prosthesis (nowadays known as Artimis®), designed to treat chronic knee pain, received the Breakthrough Device Designation from the FDA. The designation demonstrates the innovation potential of this implant and expedites US market access by receiving a priority treatment at the FDA.
January 20th, 2020
The US Food & Drug Administration identifies the Trammpolin® meniscus prosthesis as a unique and potentially more effective treatment for knee osteoarthritis patients with a deficient meniscus. At the moment there is no effective treatment available for a large group of these patients.
CEO Jan Hunik is excited to receive the Breakthrough Device Designation: “We still have quite some work to do before we can access the US market and obtain the CE mark for the European market. This designation endorses our conviction that the Trammpolin meniscus prosthesis can make an important impact on the lives of patients suffering from chronic knee pain. We look forward to the more intense collaboration with the FDA and are confident that this will expedite our US timelines.”
The goal of the Breakthrough Device Designation program is to provide patients and their health care providers with timely access to effective medical innovations. The designation ensures a predictable and timely assessment by the FDA. The Trammpolin meniscus prosthesis will have priority in upcoming FDA reviews. The FDA will also give more transparency with respect to the required data for market access of ATRO Medical’s meniscus implant.
Knee Osteoarthritis (KOA) is an irreversibly debilitating disease and is one of the leading causes of disability in Europe and the US. The Trammpolin meniscus prosthesis is a durable anatomically shaped implant that aims to reduce knee pain and restore mobility. Trammpolin is currently being assessed in a first clinical study in the Netherlands. A next study will most likely include clinics in other European countries as well as the United States. ATRO Medical is largely financed by venture capital and is expected to organize a next investment round (Series B) in 2021 to further accelerate its path to the EU and US market.
About ATRO Medical
ATRO Medical is a spin-out from DSM and Radboudumc with offices in Nijmegen and Uden (NL). The company builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials (BMM) that started in 2010 with a consortium of universities, companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has led to the development of the Trammpolin Meniscus Prosthesis and the foundation of ATRO Medical in 2016. More information can be found on www.atromedical.com.
Contacts
Maarten van der Zanden, Market Development manager
T: +316 3735 3787 E: maarten.vanderzanden@atromedical.com
**Trammpolin® is nowadays known as Artimis®
Share this article
Do you want to read more?
View related articles here
Dutch meniscus prosthesis receives FDA Breakthrough Device Designation
Patients
Dutch medical innovations are rarely granted the Breakthrough Designation by the FDA. Startup ATRO Medical from Nijmegen is the new kid on the block in orthopedics. This week their Trammpolin® meniscus prosthesis (nowadays known as Artimis®), designed to treat chronic knee pain, received the Breakthrough Device Designation from the FDA. The designation demonstrates the innovation potential of this implant and expedites US market access by receiving a priority treatment at the FDA.
EUROSTARS grants funding for first lateral meniscus prosthesis
Professionals
An international consortium led by the Dutch med-tech startup ATRO Medical receives over € 800,000 EUROSTARS funding to address an unmet need for Knee Osteoarthritis patients. These patients often suffer from cartilage degradation related to a dysfunctional meniscus. Based on previous research, the consortium will develop a durable meniscus prosthesis for the outer knee compartment to relief pain and restore mobility. This would change the life of thousands of osteoarthritis patients.
ATRO Medical Named Awardee in the Johnson & Johnson Innovation Veterans Lead QuickFire Challenge
Professionals
Yess!! ATRO Medical has been named an Awardee in the Veterans Lead QuickFire Challenge organized by Johnson & Johnson Innovation!
The Dutch Arthritis Society supports further development of the meniscus prosthesis of ATRO Medical
Patients
Orthopedic startup ATRO Medical enters a partnership together with the Dutch Arthritis Society for further development of the artificial meniscus. The Dutch startup works on a meniscus prosthesis for people with knee arthritis. The Dutch Arthritis Society supports these developments and shares its experience as patient expert in the field of arthritis.
Meniscus prosthesis receives € 2.5 million EU grant
Professionals
The European Commission grants € 2.5 million to ATRO Medical for the accelerated development of their artificial meniscus. The Dutch startup works on the first anatomical meniscus prostheses for patients with chronic knee pain. Their ground-breaking innovation continues to attract international attention, paving the way towards full-scale healthcare implementation.
Do you want to stay informed?
Sign up for our newsletter
ATRO Medical B.V.
We are an innovative medical device company that was was founded in 2016. The lead product is the Artimis® meniscus prosthesis.
Contact details
Novio Tech Campus
Transistorweg 5, 6534 AT Nijmegen (Headquarters)
Liessentstraat 9a, 5405 AH Uden (Registered office)
info@atromedical.com
Navigation
Newsletter
Stay informed of the latest news and development regarding Artimis®!
